Pharsight

Mydayis generic

Mydayis is an anti-attention deficit hyperactivity disorder (ADHD) medication owned by Takeda Pharms Usa. It contains active ingredients such as Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, and Dextroamphetamine Sulfate. Mydayis was first authorized for market use on June 20, 2017.

When will Mydayis generic be available?

The generic version of Mydayis is expected to release after August 24, 2029, upon the expiration of the 'US8846100' patent labeled as 'Controlled dose drug delivery system'. This happens to be the last patent of Mydayis which expires on that date.

Mydayis uses

Mydayis is used in the treatment of ADHD. Its active ingredients, namely Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, and Dextroamphetamine Sulfate, work synergistically to enhance focus, attention, and help manage behavioral problems associated with ADHD.

Mydayis patent expiration

Mydayis has three patents that cover its formulation and controlling drug delivery system; one of these patents has already expired. The last patent due to expire is 'US8846100: Controlled dose drug delivery system' on August 24, 2029, paving the way for Mydayis generics to enter the market. Below are the details of the patent:

Litigations filed on Mydayis

Mydayis dosage

Want to ask something?